RT期刊文章SR电子T1使用Apixaban和华法林的患者接受过程:从亚里士多德(i2 - 2.003)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP i2 - 2.003签证官82是10补充A1雷纳托Lopes A1大卫·加西亚A1丹首页尼尔Wojdyla A1保罗•多里安人A1约翰亚历山大A1 Lars Wallentin A1费尔南多·拉娜A1迈克尔•汉娜A1克拉斯持有A1克里斯托弗·格兰杰年2014 UL //www.ez-admanager.com/content/82/10_Supplement/I2-2.003.abstract AB目的:检查的调查过程和随后的中风的风险和系统性栓塞(SSE)和主要出血在亚里士多德(Apixaban减少中风和其他房颤血栓栓塞事件)。背景:上交所相关的风险与华法林停止程序被认为是低;然而,很少有人知道apixaban接受程序的患者使用。方法:使用数据从亚里士多德的18201名患者(平均随访:1.8岁),我们描述了最常见的程序,中风的风险和主要出血在接下来的30天,以及使用桥接治疗。我们分类程序为“主要”,如果他们需要全身麻醉或被认为构成显著的术后出血的风险。调查人员作为“新兴”或“non-emergent分类过程。”结果:11417例手术病人发生在6162年:477年主要(4.2%)和10940年(95.8%)non-major;322(2.8%)紧急和11095 (97.2%)non-emergent。最常见的程序都拔牙/口腔外科,结肠镜检查,胃镜检查,眼科手术。4082年手术(35.8%),研究药物并没有停止。 Median time of study drug stop was 4 days peri-procedure for both treatment groups. A second "bridging" anticoagulant, most commonly low-molecular-weight heparin, was used in 1335 procedures (11.7%). Of 5660 events with apixaban, SEE and major bleeding were associated with 0.43% and 1.55%, respectively; of 5757 events with warfarin, corresponding values were 0.56% and 1.80%, respectively. CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups. Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr. Lopes has received personal compensation for activities with AstraZeneca, Bayer Pharmaceuticals Inc., Boehringer Ingleheim Pharmaceuticals Inc., Bristol-Myers Squibb Co., and Pfizer Inc. as a consultant. Dr. Lopes has received research support from Bristol-Myers Squibb Co., and GlaxoSmithKline Inc. Dr. Garcia has received personal compensation for activities with Bristol-Myers Squibb Co., Pfizer INc., Boehringer Ingelheim INc., Daiichi Pharmaceutical Corp., Janssen, CSL Behring, and Roche Diagnostics Corp. Dr. Wojdyla has nothing to disclose. Dr. Dorian has received personal compensation for activities with Bayer Pharmaceuticals Corp., BI, Bristol-Myers Squibb Co., and Pfizer Inc. Dr. Alexander has received personal compensation for activities with Bristol-Myers Squibb Company, Pfizer Inc, Merck & Co., Inc., Schering-Plough Corporation, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Ortho-McNeil, Janssen Pharmaceutica, Polymedix, Regado Biosciences, and Bayer Pharmaceuticals Corporation. Dr. Alexander has received research support from from Bristol-Myers Squibb Company, Merck & Co., Inc., Schering-Plough Corporation, and Regado Briosciences. Dr. Wallentin has received personal compensation for activities with Abbott, Athera Biotechnologies, Merck & Co. Inc., and Regado Biosciences, AstraZeneca, Bristol-Myers Squibb Co./Pfizer Inc., GlaxoSmithKline Inc. Dr. Wallentin has received research support from AstraZeneca, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Co./Pfizer Inc., GlaxoSmithKline Inc., and Merck & Co. Inc. Dr. Lanas has nothing to disclose. Dr. Hanna has received personal compensation for activities with Bristol-Myers Squibb Co. as an employee. Dr. Hanna holds stock and/or stock options in Bristol-Meyers Squibb Co. which sponsored research in which Dr. Hanna was involved as an investigator. Dr. Held has received personal compensation for activities with AstraZeneca. Dr. Held has received research support from AstraZeneca, Merck & Co. Inc., GlaxoSmithKline Inc., Roche Diagnostics Corp., and Bristol-Myers Squibb Co. Dr. Granger has nothing to disclose.Sunday, April 27 2014, 1:00 pm-5:00 pm